Skip to Content
  • Prev Rank-
  • Location
    Cheshire, Conn.
  • Industry
    Pharmaceuticals
  • Sector
    Health Care
  • F1000 Rank-
  • G500 Rank-
  • Current Streak-

Is it a bird? Is it a plane? No, it’s Soliris: Alexion Pharmaceuticals sells just one drug, and in the first six months of this year it pulled in global revenues of $1.1 billion, just a few hundred thousand dollars shy of what it generated for all of 2012 (and that was double what it sold in 2010). Alexion’s wonder drug, Soliris, was first approved by the FDA in 2007 for the treatment of a rare blood disorder; treatment of a second rare genetic disorder was added in 2011. The company attributes Soliris’s meteoric rise to more doctors around the world prescribing it for more of their patients – simple. —N.S.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
Cheshire, Conn.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-

Revenue, Net Income

Revenue Past Four Quarters
1779
Net Income Past Four Quarters330

Growth Rates & Ranks

EPS Growth Rank56
EPS 3 yr Annual Growth Rate Pct46
Revenue Growth Rank23
Rev 3 yr Annual Growth Rate43
Total Return 3 yr Annual Rate49
Total Return Rank
22
Beat S&P 3 yr Annual Growth Rate?
yes
P/E current fiscal year profits (est.)
36.9